Britain and America have announced a significant bilateral deal that will guarantee zero levies on British drug shipments entering the US market.
Key Provisions of the Accord
As part of the deal, the UK has pledged to boost spending on medicines through the National Health Service (NHS). This commitment ensures that import taxes on these key goods will remain at nothing for a duration of three years.
This agreement follows earlier threats to significantly raise tariffs on branded drug products, with figures discussed up to double the cost.
"This agreement between the UK reinforces the international landscape for cutting-edge drugs and introduces much-needed balance to American-British pharmaceutical trade," a release noted.
Commercial Importance
Drugs constitute one of the the United Kingdom's biggest goods shipped to the US, which is clearly the primary buyer for large British pharmaceutical firms.
Statistics show that in the 12 months to the end of last September, the UK sold drugs worth over eleven billion pounds to the US. This value made up 17.4% of British export trade in that timeframe.
"This guarantee secures employment, increases funding and facilitates the UK to establish itself as a international leader for medical research," a minister remarked.
Key British Pledges
The agreement entails several key changes from the British government:
- Revised Affordability Limit: The UK will lift the price threshold at which it considers new medicines to be unaffordable by 25%.
- Boosted Medicine Funding: There is a aim to double overall health service expenditure on medicines from 0.3% of the national economy to 0.6% over the following ten-year period.
- Payback Limit: The sum drug companies must pay back to the NHS to control costs will be capped at 15%. Last year, refunds exceeded 20%.
Industry Background
The deal comes amid a ongoing row between the pharmaceutical industry and the UK government over medicine costs and NHS adoption.
These tensions were intensified by claims that American consumers were charged significantly more for the identical medicines than people in the other developed nations.
Over the last 18 months, several major manufacturing plans in the UK have been halted or cancelled, while substantial funding commitments have been pledged toward projects in the United States.
A senior figure stated that the NHS had to increase expenditure on medicines, noting that its spending on drugs had declined as a percentage of its overall budget over the past decade.
